Sharp Packaging Services has purchased a range of serialization solutions from TraceLink, a track and trace network for the life sciences supply chain, to prepare for the next phase of requirements under the U.S. Drug Supply Chain Security Act (DSCSA). TraceLink solutions aim to help eliminate point-to-point integration complexities and reduce business risk or Sharp’s Commercial Packaging and Clinical Services business in the U.S., UK, and Europe.

In November 2017, DSCSA regulations will require the serialization of all drug products and enhanced verification of product identity by pharmaceutical companies and their CMO/CPO partners.

“We needed a cost-effective track and trace solution provider that was proven in ensuring supply chain protection and risk mitigation, with the agility to quickly connect and validate the brands within our infrastructure,” said Rick Seibert, senior vice president Innovation and Technology at Sharp. “Our partnership with TraceLink demonstrates Sharp’s ongoing commitment to deliver on its mission of providing quality products and services to our customers, while complying with the most demanding global and U.S. requirements for drug serialization.”

“Sharp is a forward thinking industry leader for serialization and recognized the critical need to migrate from its point-to-point serialization system to an interoperable, integrate-once network platform with Tracelink, in order to be fully prepared for the next phase of DSCSA,” said Shabbir Dahod, president and chief executive officer of TraceLink. “As the only digital supply chain network solution that provides scalability at the operational level, TraceLink was chosen by Sharp to help maintain their global efficiencies, keep costs low and meet the complex compliance demands of their growing customer base.”

Visit Sharp at Table 122